IMF Videos Search Content For Healthcare Professional (134) Healthcare Provider (134) Care Partner (69) Patient (69) Series - Any - ASCO/EHA (52) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (186) Financial Considerations (15) Frontline Therapy (84) Health Equity (34) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (72) Lifestyle (47) Mental & Emotional Health (29) Myeloma 101 (59) Myeloma in the News (8) Public Policy & Advocacy (17) Q&A's (43) Recorded Seminars & Workshops (15) Recorded Webinars (24) Relapse/Refractory Myeloma (138) Research Updates (194) Symptom Management (115) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (70) High-Risk Myeloma (47) High-risk Smoldering Myeloma (40) Late Relapse (4–6 Lines of Therapy) (86) MGUS (41) Newly Diagnosed (Pre-Treatment or First Treatment) (65) Smoldering Myeloma (51) Types of Therapy Immunomodulatory drugs (IMiDs) (62) Immunotherapies (CAR T; BiTE, etc.) (102) Monoclonal antibodies (56) Proteasome inhibitors (48) Stem cell transplant (40) Steroids (42) Supportive Care (43) Year Published 2026 (22) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance MagnetisMM-30, a Phase 1b Study of ELRA and IBER Combination in Relapsed Refractory Multiple Myeloma July 15, 2024 ASCO/EHA DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse July 12, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 28, 2024 ASCO/EHA Phase I Study: Dual Targeting BCMA & CD19 FASTCAR-T for High-Risk Multiple Myeloma June 27, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 24, 2024 ASCO/EHA Class comparison of BCMA-directed therapies in relapsed multiple myeloma June 24, 2024 ASCO/EHA MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma June 21, 2024 ASCO/EHA Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed Refractory Multiple Myeloma June 21, 2024 ASCO/EHA LINKER-MM1: Linvoseltamab for RR Multiple Myeloma Deep, Durable Responses at 14-Month Follow-Up June 20, 2024 ASCO/EHA Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study June 19, 2024 ASCO/EHA IMROZ: Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma June 17, 2024 ASCO/EHA DREAMM-8 Study: Belantamab mafodotin plus pomalidomide and dexamethasone shows improved outcomes in relapsed/refractory multiple myeloma June 14, 2024 ASCO/EHA Load More
